Company Encyclopedia
View More
name
BriaCell Therapeutics
BCTX.US
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer.
1.875 T
BCTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Briacell And Receptor.Ai To Collaborate On Ai Driven Small Molecule Cancer Therapeutics

    Briacell Therapeutics Corp :BRIACELL AND RECEPTOR.AI TO COLLABORATE ON AI DRIVEN SMALL MOLECULE CANCER THERAPEUTICS

    Reuters·
    US
    BCTX
    -0.57%
    Reuters·
    US
    BCTX
    -0.57%

    Stocks in Play: BriaCell Therapeutics Corp.

    11:29 AM EST - BriaCell Therapeutics Corp. : Will be presenting three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS®) taking place from December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio. BriaCell Therapeutics Corp. shares T.BCT are trading down $0.53 at $10.87.

    Baystreet·
    US
    BCTX
    -0.57%
    Baystreet·
    US
    BCTX
    -0.57%

    BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

    PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( Nasdaq: BCTX, BCTXW, BCTXZ ) ( TSX: BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is ...

    GlobeNewswire·
    US
    BCTX
    -0.57%
    GlobeNewswire·
    US
    BCTX
    -0.57%

    BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer | BCTX Stock News

    BriaCell Therapeutics Corp. has received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) for its Phase 3 study of Bria-IMT combined with an immune checkpoint inhibitor in metastatic breast cancer. This marks the fourth consecutive positive recommendation, indicating no safety concerns. The study is conducted under FDA Fast Track Designation, highlighting the urgent medical need in this area. BriaCell's CEO expressed confidence in the safety and potential of Bria-IMT to transform cancer care for patients in need.

    StockTitan·
    US
    BCTX
    -0.57%
    StockTitan·
    US
    BCTX
    -0.57%

    BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer | BCTX Stock News

    BriaCell Therapeutics Corp. has announced a collaboration with Memorial Sloan Kettering Cancer Center’s Therapeutics Accelerator to advance its Bria-OTS+™ platform for breast cancer and other indications. The partnership will support manufacturing, IND development, and clinical trials for Bria-BRES+, a personalized immunotherapy for metastatic breast cancer. This collaboration aims to leverage MSK's expertise to expedite the clinical development of Bria-OTS+, addressing the urgent needs of cancer patients.

    StockTitan·
    US
    BCTX
    -0.57%
    StockTitan·
    US
    BCTX
    -0.57%